Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrocortisone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 3/20 | 0.88 |
| ▸ | HIF1A | Q16665 | 12/20 | 0.88 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.88 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.88 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.88 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.88 |
| ▸ | PGR | P06401 | 3/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.88 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.88 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.88 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.88 |
| ▸ | SHBG | P04278 | 2/20 | 0.88 |
| ▸ | MAPT | P10636 | 2/20 | 0.88 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.80 |
| ▸ | TSHR | P16473 | 2/20 | 0.80 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | AR | P10275 | 1/20 | 0.70 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.70 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrocortisone SCHEMBL3105433 | 1.00 | HIF1A (0.88) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL364232 | 1.00 | HIF1A (0.88) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL5578673 | 1.00 | HIF1A (0.88) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL41084 | 1.00 | HIF1A (0.88) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL24900238 | 0.94 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL6932400 | 0.94 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL1688689 | 0.94 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL12737556 | 0.94 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL10261067 | 0.94 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL5699764 | 0.94 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 762 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352645-B2 | Compositions and methods for treating Leber's hereditary optic neuropathy | Wuhan Neurophth Biotechnology Limited Company (CN) | 2022-06-07 | — | — | US | claimed |
| EP-3840785-A1 | COMPOSITIONS AND METHODS FOR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY | Wuhan Neurophth Biotechnology Limited Company (CN) | 2021-06-30 | — | — | EP | claimed |
| US-20210189429-A1 | COMPOSITIONS AND METHODS FOR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY | Wuhan Neurophth Biotechnology Limited Company (CN) | 2021-06-24 | — | — | US | claimed |
| WO-2020038352-A1 | COMPOSITIONS AND METHODS FOR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY | WUHAN NEUROPHTH BIOLOGICAL TECHNOLOGY LIMITED COMPANY (CN) | 2020-02-27 | — | — | WO | claimed |
| US-7745138-B2 | Methods for determining drug responsiveness | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-06-29 | — | — | US | claimed |
| US-20100152100-A1 | ACCELERATED THERAPY | GLOUCESTER PHARMACEUTICALS, INC. | 2010-06-17 | — | — | US | claimed |
| WO-2010047714-A1 | CANCER THERAPY | GLOUCESTER PHARMACEUTICALS (US) | 2010-04-29 | — | — | WO | claimed |
| WO-2010014819-A1 | ACCELERATED THERAPY | GLOUCESTER PHARMACEUTICALS, INC. (US) | 2010-02-04 | — | — | WO | claimed |
| US-20090286248-A1 | Methods for Determining Drug Responsiveness | THE TRUSTEES OF THE UNIVERSITY OF PENSYLVANIA | 2009-11-19 | — | — | US | claimed |
| EP-2117556-A2 | COMBINATION THERAPY COMPRISING ROMIDEPSIN AND I.A. BORTEZOMIB | Gloucester Pharmaceuticals, Inc. (US) | 2009-11-18 | — | — | EP | claimed |
| US-20090105200-A1 | Combination therapy | GLOUCESTER PHARMACEUTICALS | 2009-04-23 | — | — | US | claimed |
| WO-2008091620-A2 | COMBINATION THERAPY COMPRISING ROMIDEPSIN AND I.A. BORTEZOMIB | GLOUCESTER PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | WO | claimed |
| US-6878518-B2 | Methods for determining steroid responsiveness | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2005-04-12 | — | — | US | claimed |
| US-20040203031-A1 | Methods for determining drug responsiveness | UNIVERSITY OF PENNSYLVANIA | 2004-10-14 | — | — | US | claimed |
| WO-2003062792-A2 | METHODS FOR DETERMINING DRUG RESPONSIVENESS | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2003-07-31 | — | — | WO | claimed |
| US-20030138781-A1 | Methods for determining steroid responsiveness | UNIVERSITY OF PENNSYLVANIA | 2003-07-24 | — | — | US | claimed |
| EP-4382601-A1 | COMPOSITION AND METHOD FOR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY CAUSED BY ND4 MUTATION | Wuhan Neurophth Biotechnology Limited Company (CN) | 2024-06-12 | — | — | EP | disclosed |
| CN-116024266-A | Compositions and methods for treating leber's hereditary optic neuropathy due to ND4 mutations | 武汉纽福斯生物科技有限公司 | 2023-04-28 | — | — | CN | disclosed |
| WO-2001046475-A1 | TREFOIL DOMAIN-CONTAINING POLYNUCLEOTIDES, POLYPEPTIDES, AND ANTIBODIES | HUMAN GENOME SCIENCES, INC. (US) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001046254-A1 | TRANSFERRIN POLYNUCLEOTIDES, POLYPEPTIDES, AND ANTIBODIES | HUMAN GENOME SCIENCES, INC. (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105200-A1 | Combination therapy | MCL1, BCL3, PSMB5 | NR3C1 480/4885HIF1A 3574/4885HSD17B10 2491/4885 |
| US-20100152100-A1 | ACCELERATED THERAPY | LPXN, PSAP, ERAP1 | NR3C1 1064/4885HIF1A 1621/4885HSD17B10 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.